Experimental pill promises new hope for deadly pancreatic cancer
Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.
Original Source
Read the full article at Cnbc →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.